Business Summary
|
Resverlogix Corp. (Resverlogix) is a biotechnology company developing technology platforms and intellectual property for global medical markets with unmet medical needs. The Company’s primary focus is in the research, development and commercialization of therapeutics that address the risk of cardiovascular disease (CVD). Its secondary research focus is on inflammatory diseases. NexVas Plaque Reduction is its primary program for the development of drugs that increase the production of ApoA-I to reduce the risk of cardiovascular diseases. NexVas Vascular Inflammation is its second CVD program, a discovery stage technology for the development of drugs that target molecular markers of inflammation. ReVas is its third CVD program, a research stage technology for the development of therapeutics. NexVas Alzheimer’s Disease is a discovery-stage technology for the development of drugs that enhance ApoA-I for stabilization and regression of Beta Amyloid Plaque.
| | (Source: ARS)
|
|
|
